WO2003061560A3 - Replication competent dual-ad vectors for vaccine and immunotherapy applications - Google Patents

Replication competent dual-ad vectors for vaccine and immunotherapy applications Download PDF

Info

Publication number
WO2003061560A3
WO2003061560A3 PCT/US2002/033079 US0233079W WO03061560A3 WO 2003061560 A3 WO2003061560 A3 WO 2003061560A3 US 0233079 W US0233079 W US 0233079W WO 03061560 A3 WO03061560 A3 WO 03061560A3
Authority
WO
WIPO (PCT)
Prior art keywords
vectors
composition
vector
vaccine
dual
Prior art date
Application number
PCT/US2002/033079
Other languages
French (fr)
Other versions
WO2003061560A2 (en
Inventor
Sybille Sauter
Xiangming Fang
Amena Rahman
Nathan P Englund
Scott Gallichan
Mark I Fitchmun
Robert E Sobol
Original Assignee
Genstar Therapeutics Corp
Sybille Sauter
Xiangming Fang
Amena Rahman
Nathan P Englund
Scott Gallichan
Mark I Fitchmun
Robert E Sobol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genstar Therapeutics Corp, Sybille Sauter, Xiangming Fang, Amena Rahman, Nathan P Englund, Scott Gallichan, Mark I Fitchmun, Robert E Sobol filed Critical Genstar Therapeutics Corp
Priority to AU2002365260A priority Critical patent/AU2002365260A1/en
Publication of WO2003061560A2 publication Critical patent/WO2003061560A2/en
Publication of WO2003061560A3 publication Critical patent/WO2003061560A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A composition for targeting one or more infectious agent(s) or target cell(s) comprising a complementary set of adnoviral vectors, wherein each vector is dependent upon the other for replication. The first vector of the pair may comprise an E1 expression cassette where E1 is expressed within one or more infectious agent(s) or target cell(s) from a promoter and does not express other adenoviral proteins. The second vector provides adenoviral proteins required for packaging and replication. As such, the composition is useful for the delivery and expression of prophylactic and/or therapeutic genes, some of which demonstrate direct cytotoxic effects, indirect cytotoxic effects of other treatments. The composition may encode one or more antigen(s), with or without immunomodulatory genes, to induce one or more immune response(s) to the encoded antigen or antigens.
PCT/US2002/033079 2001-10-16 2002-10-16 Replication competent dual-ad vectors for vaccine and immunotherapy applications WO2003061560A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002365260A AU2002365260A1 (en) 2001-10-16 2002-10-16 Replication competent dual-ad vectors for vaccine and immunotherapy applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32979801P 2001-10-16 2001-10-16
US60/329,798 2001-10-16

Publications (2)

Publication Number Publication Date
WO2003061560A2 WO2003061560A2 (en) 2003-07-31
WO2003061560A3 true WO2003061560A3 (en) 2007-10-18

Family

ID=23287062

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2002/033079 WO2003061560A2 (en) 2001-10-16 2002-10-16 Replication competent dual-ad vectors for vaccine and immunotherapy applications
PCT/US2002/033162 WO2003033029A1 (en) 2001-10-16 2002-10-16 Replication competent dual-ad vectors for vaccine and immunotherapy applications

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033162 WO2003033029A1 (en) 2001-10-16 2002-10-16 Replication competent dual-ad vectors for vaccine and immunotherapy applications

Country Status (5)

Country Link
EP (1) EP1450862A4 (en)
JP (1) JP2005511534A (en)
AU (1) AU2002365260A1 (en)
CA (1) CA2463996A1 (en)
WO (2) WO2003061560A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8302354U (en) 2003-09-17 2004-05-18 Orlando Rossi Jr Improvement introduced in phototherapeutic light source for treatment of hyperbilirubinemia
MX2010008168A (en) 2008-01-25 2011-02-24 P53 Inc P53 biomarkers.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035028A2 (en) * 1997-02-10 1998-08-13 Baxter International Inc. An oncolytic/immunogenic complementary-adenoviral vector system
WO2001092550A2 (en) * 2000-05-31 2001-12-06 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035028A2 (en) * 1997-02-10 1998-08-13 Baxter International Inc. An oncolytic/immunogenic complementary-adenoviral vector system
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US20020142989A1 (en) * 1997-02-10 2002-10-03 Genstar Therapeutics Corp. Oncolytic/immunogenic complementary-adenoviral vector system
WO2001092550A2 (en) * 2000-05-31 2001-12-06 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
US20020042139A1 (en) * 2000-05-31 2002-04-11 Higginbotham James N. Methods and compositions for efficient gene transfer using transcomplementary vectors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALEMANY R.: "Complementary adenoviral vectors for oncolysis", CANCER GENE THERAPY, vol. 6, no. 1, January 1999 (1999-01-01) - February 1999 (1999-02-01), pages 21 - 25, XP001037527 *

Also Published As

Publication number Publication date
EP1450862A1 (en) 2004-09-01
AU2002365260A1 (en) 2003-09-02
WO2003061560A2 (en) 2003-07-31
AU2002365260A8 (en) 2007-12-20
EP1450862A4 (en) 2005-03-02
WO2003033029A1 (en) 2003-04-24
CA2463996A1 (en) 2003-04-24
JP2005511534A (en) 2005-04-28

Similar Documents

Publication Publication Date Title
WO2006078279A8 (en) Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
MY119003A (en) Bacterial antigens and vaccine compositions
AU3431497A (en) DNA immunization against Chlaymdia infection
EP1335023A3 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
EA200901060A1 (en) NEW METHOD AND COMPOSITIONS
WO1999058658A3 (en) Expression vectors for stimulating an immune response and methods of using the same
AU2001295671A1 (en) Pharmaceutical composition for immunisation against aids
EP1363660A4 (en) Superior molecular vaccine based on self-replicating rna, suicidal dna or naked dna vector, that links antigen with polypeptide that promotes antigen presentation
WO2005012537A3 (en) Adenoviral vector-based vaccines
EE200200507A (en) Modified Vaccine Virus Ankara (MVA), an Inhibited Host Cell and a Pharmaceutical Composition Containing it, Preparation and Therapeutic Use of MVA
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2008020335A3 (en) Immunogenic compositions for streptococcus agalactiae
WO2004083404A3 (en) Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain
EP3922724A4 (en) Recombinant vector containing african swine fever virus immunogenic protein, recombinant bacteria, and application thereof
WO2003007869A3 (en) Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres
WO2002078631A3 (en) Improved conditionally replicating vectors for inhibiting viral infections
ZA200706389B (en) Compositions for immunizing against mycobacterium
WO2004018630A3 (en) Recombinant double-stranded rna phages and uses thereof
WO2000063406A3 (en) Adenoviral vectors having nucleic acids encoding immunomodulatory molecules
WO2003061560A3 (en) Replication competent dual-ad vectors for vaccine and immunotherapy applications
WO2004018627A3 (en) Methods for propagating adenovirus and virus produced thereby
WO1999051745A3 (en) Dna immunization against chlamydia infection
WO2003072789A3 (en) Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTIFICATION OF LOSS OF RIGHTS PERSUANT TO RULE 69(1) EPC (EPO FORM 1205A SENT ON 08.09.04)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP